查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1445527

術後疼痛市場評估：按產品、給藥途徑、分銷管道和地區劃分的機會和預測（2017-2031）

Postoperative Pain Market Assessment, By Product, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 235 Pages | 商品交期: 3-5個工作天內

價格

全球術後疼痛市場規模將從2023年的400.9億美元成長到2031年的603.6億美元，2024-2031年預測期內複合年增長率為5.25%，預計規模將持續成長。

由於外科手術的增加導致對有效疼痛緩解策略的高需求以及需要有效術後疼痛控制的慢性疾病的增加等因素，預計該市場將增長。 此外，對阿片類藥物濫用的擔憂導致人們越來越有興趣探索非阿片類藥物用於術後疼痛管理的選擇。 透過減輕術後疼痛來提高患者依從性也是推動市場的一個主要因素。 推動產業創新的研發措施也提供了減少術後不適的新方法，有助於市場的進一步成長。 另一方面，市場成長的主要障礙是與使用鴉片類止痛藥相關的副作用以及與使用疼痛管理解決方案相關的其他併發症。 由於疼痛管理使用作用於神經系統的藥物，因此藥物濫用也是一個主要問題和監管挑戰。

2023年10月，Hyloris Pharma宣布其術後疼痛治療藥物Maxigesic IV獲得美國FDA核准。 Maxigesic IV 是一種靜脈注射藥物，結合了撲熱息痛和布洛芬溶液，可減輕術後疼痛和炎症，且沒有阿片類藥物成癮的風險。 Hyloris Pharma 是一家總部位於比利時的公司，與紐西蘭藥品製造商 AFT Pharmaceuticals 和 Hikma Pharmaceuticals 合作開發了該核准藥物。

當單獨的藥物治療不夠時，需要進行許多手術。 全球需要手術治療的癌症病例（例如咽癌和口腔癌）數量正在增加。 心血管和胃腸道疾病等慢性疾病的增加以及需要手術的交通事故的數量也推動了對一次性手術器械的需求。 大量手術與大量術後疼痛病例直接相關，預計術後疼痛市場將因兩者的增加而擴大。 根據世界衛生組織 (WHO) 統計，全世界每年進行超過 3 億例外科手術。 根據現有數據，2022年美國進行了超過700萬個例外科手術。

隨著對病人依從性的日益重視，術後疼痛管理已成為一個主要問題。 許多患者術後出現中度至重度疼痛，顯示術後疼痛控制不足。 造成這問題的主要原因是止痛藥處方不足，不遵守規定並不是唯一原因。 疼痛評估、記錄和管理是護理的重要方面，因為出院後患者的疼痛管理可能會被忽略。 遵守術後患者疼痛評估至關重要，建議使用標準量表。 充足的鎮痛藥物和批准的國家疼痛指南對於有效的疼痛管理至關重要。 參與公司不斷致力於產品開發和監管回應，以更好地回應市場需求。

從產品類型來看，製藥業預計將佔據主導地位，因為它比設備使用更廣泛。 阿片類藥物、非類固醇類抗發炎藥 (NSAID) 等鎮痛藥比疼痛管理設備更容易獲得且更具成本效益。 該藥物不需要醫療幫助，易於給藥，這也有助於其高利用率。 另一方面，為了避免與藥物相關的副作用而採用疼痛管理設備的情況也在增加，從而提高了疼痛管理設備行業的成長率。 由於疼痛管理設備的日益普及、易於獲取、患者依從性和成本效益，預計製藥業將佔據主導地位。

本報告調查了全球術後疼痛市場，提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構以及影響市場成長的因素。我們編制分析、案例研究、競爭格局、主要公司概況等。

目錄

第 1 章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第 4 章全球術後疼痛市場展望

  • 市場規模/預測
  • 按產品
    • 藥品
    • 設備
  • 依給藥途徑
    • 注射
    • 口頭
    • 本地
    • 透皮
    • 其他
  • 按分銷管道
    • 醫院藥房
    • 零售藥局
    • 網路藥局
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 按公司劃分：市場佔有率 (%)，2023 年

第 5 章全球術後疼痛市場展望：按地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東/非洲

第 6 章市場映射

  • 按產品
  • 依給藥途徑
  • 按分銷管道
  • 按地區

第 7 章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 生長促進因素（問題、限制因素）

第 9 章監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第 10 章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（5 家參與公司）

第 11 章價格分析

第 12 章案例研究

第 13 章主要公司展望

  • Novartis AG
  • Allergan plc
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson Pte. Ltd.
  • AstraZeneca PLC
  • Sanofi S.A.
  • Cipla Inc. (InvaGen Pharmaceuticals Inc.)

第 14 章策略建議

第 15 章關於我們公司/免責聲明

Product Code: MX11076

Global postoperative pain market is projected to witness a CAGR of 5.25% during the forecast period 2024-2031, growing from USD 40.09 billion in 2023 to USD 60.36 billion in 2031. The market is anticipated to thrive under the influence of factors such as the increasing number of surgical procedures leading to high demands for efficient pain relief strategies and a rise in chronic conditions contributing to the necessity for effective post-surgical pain control. Additionally, concerns regarding opioid abuse have led to increased interest in exploring non-opioid alternatives for managing pain after surgery. Emphasis on improving patient compliance through eliminating post-operative pain is another major driving force for the market. Research and development initiatives driving innovation within the industry, providing novel approaches to reduce post-operative discomfort further expand the market. However, the major challenge for market expansion is the side effects associated with the use of opioid analgesic drugs and other complications with the use of pain management solutions. Drug abuse is another major concern related to pain management therapies as these methods involve the use of drug agents acting on the nervous system, leading to regulatory challenges.

For instance, in October 2023, Hyloris Pharma announced that it had received US FDA approval for the drug Maxigesic IV, which is meant to treat post-operative pain. Maxigesic IV contains a combination of paracetamol with ibuprofen solution for intravenous infusion, which helps in reducing postoperative pain and inflammation without the risk of opioid addiction. Hyloris Pharma is a Belgium-based company, and it developed the approved drug in collaboration with New Zealand-based drugmaker AFT Pharmaceuticals and Hikma Pharmaceuticals.

Increasing Number of Surgical Procedures

Most surgeries are necessary due to emergencies or other situations where only medication is not enough. The number of cancer cases requiring surgery, such as throat or mouth cancer, is rising globally. The demand for disposable surgical instruments is further propelled by chronic conditions like cardiovascular and gastrointestinal issues, and the surge in traffic accidents necessitating surgery. The market's significant expansion is aided by consumers' disposable income, which enables them to purchase these instruments. A high number of surgical procedures performed is directly linked with a high incidence of postoperative pain cases, and as the increase in both numbers is observed, the market expansion is promising. According to the World Health Organization (WHO), over 300 million surgical procedures are done globally annually. In October 2023, as per The Hindu, the rate of surgeries in India is between 166 and 3,646 surgeries per 100,000 individuals, depending on the setting, population, and other factors, while the population is about 1.4 billion. As per available data, more than 7 million surgical procedures were performed in the year 2022 within the United States.

Increasing Emphasis on Patient Compliance

Due to the rising emphasis on patient compliance, postoperative pain management has become a major concern. Many patients still experience moderate to severe pain after surgery, indicating inadequate postoperative pain management. The primary cause of this issue is insufficient analgesia prescription, not solely non-compliance. Patients' pain management can be neglected after discharge, so pain assessment, recording, and management are crucial aspects of care. Compliance with pain assessment in postoperative patients is vital, and the use of standard scales is recommended. Adequate analgesics and approved national pain guidelines are essential for effective pain management. Market players are constantly involved in product development and regulatory pathways to adequately cater to the market requirements.

In February 2024, Hikma Pharmaceuticals PLC announced the launch of COMBOGESIC IV injection in the United States market. COMBOGESIC IV is an opioid-free pain relief intravenous injection with a combination of 1000 mg acetaminophen and 300 mg ibuprofen. The combination drug was approved by the United States FDA in October 2023 for use in adults. Hikma Pharmaceuticals is a multinational pharmaceutical manufacturer working in a variety of indications and has a strong presence in the United States.

Dominance of Drug Segment and Fast Growth for Devices Segment

In the postoperative pain market, drugs are expected to dominate the product type category due to their extensive use in pain management compared to devices. Painkiller drugs, such as opioids, NSAIDs, and analgesics, are readily available and more cost-effective than pain management devices. The ease of administration without the need for medical assistance further contributes to the high usage of drugs. However, the adoption of pain management devices is increasing to avoid the side effects associated with drugs, leading to a higher growth rate in the pain management device segment. Despite the growing popularity of pain management devices, the drug segment is anticipated to dominate due to easy access, patient compliance, and cost-effectiveness.

In January 2024, Lupin launched a generic Bromfenac Ophthalmic Solution in the United States. This product is equivalent to Bausch & Lomb Inc.'s Prolensa ophthalmic solution, and it has received approval from the U.S. Food and Drug Administration. Lupin is the first company to file for this generic medication, granting it exclusive rights for 180 days. Bromfenac Ophthalmic Solution is intended to treat postoperative pain, and inflammation, along with alleviating eye discomfort in patients who have undergone cataract surgery.

Oral Route of Administration to be Leading Segment

In the management of postoperative pain, administering painkillers through the oral route is widely regarded as the most effective method, particularly if there are no contraindications. This approach excels in terms of simplicity, non-invasiveness, and patient acceptance compared to other routes such as injectables or inhalation. Oral opioids are effective in addressing acute pain, despite their slower action compared to injections. They are typically taken as pills that act rapidly or as sustained-release tablets. For better pain control, a combination of different types of pain relievers and non-drug therapies, known as multimodal analgesia, is commonly recommended over relying solely on opioids.

In February 2024, Cytogel Pharma's drug Cyt-1010 is undergoing clinical trials, specifically in Phase I for treating pain after surgery. Drugs in Phase I for this purpose typically have a high chance, around 87%, of moving forward to Phase II. Cyt-1010 is a distinct compound, like endomorphin 1, a natural pain regulator. It can be administered either orally or intravenously, interacting with Mu opioid receptors to manage pain.

North America to be the Dominating Region

North America is expected to dominate the market share throughout the assessment period owing to factors, including the high prevalence and severity of postoperative pain, the adoption of opioid management treatment to reduce the opioid epidemic, and the presence of a strong drug pipeline with effective drugs coming up for approvals by the US Food and Drug Administration. Additionally, the region has a high number of surgical procedures, increasing demand for pain management drugs, and rising awareness regarding post-surgery pain control. The presence of key market players like Novartis AG, Allergan plc., Teva Pharmaceutical Industries Ltd., Mylan N.V., and Pfizer Inc. in the region is another factor strengthening the lead of North America in the region. US FDA efforts to strengthen pain management methods also catalyze market growth.

In September 2023, the US FDA granted cooperative support to develop two clinical practice guidelines using evidence-based approaches. One guideline will focus on the treatment of recent-onset lower back pain, while the other will focus on the management of pain after laparoscopic abdominal surgery.

Future Market Scenario (2024 - 2031F)

In the future, postoperative pain management will most likely involve more acute pain services (APSs) and better communication among surgery, anesthesiology, and acute pain departments. The use of multimodal analgesics may enhance pain relief after surgery. The occurrence of chronic pain after surgery differs depending on the surgical complications but is very common. Innovative approaches, like transitional pain services, aim to improve the management of acute and chronic pain after surgery. Alongside, exploring new metabolic pathways and biological targets to provide pain relief without any drug abuse and product development seems like a promising concept for future growth of the market. For instance, in October 2023, South Rampart Pharma, a company focused on safer pain treatments, received Fast Track status for its promising drug, SRP-001, from the US FDA. SRP-001 stands out as a novel, non-addictive painkiller that operates differently from conventional opioids. The Fast Track designation is designed to accelerate the development and review process for promising therapies that address serious conditions. This pathway aims to ensure that patients have access to effective treatments quickly, thereby meeting pressing medical needs.

Key Players Landscape and Outlook

Novartis AG, Allergan plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., GlaxoSmithKline Plc., Johnson & Johnson Pte. Ltd., AstraZeneca PLC, Sanofi S.A., are some of the renowned players of the postoperative pain management market. These players actively invest time and money in innovative product developments and regulatory approvals. Market tactics like mergers and acquisitions and collaborations among market players are anticipated to further drive market expansion.

In November 2023, BehaVR and Fern Health joined forces to establish RealizedCare, a digital care management solution tailored for chronic pain. This collaboration aims to address the growing need for proven, scalable, and cost-effective interventions for mental and behavioral health issues, with an initial focus on chronic pain.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Postoperative Pain Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Product
    • 4.2.1. Drugs
      • 4.2.1.1. Opioids
      • 4.2.1.2. Cyclooxygenase-2-Selective(COX-2) Inhibitors
      • 4.2.1.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
      • 4.2.1.4. Anesthetics
      • 4.2.1.5. Anticonvulsants
      • 4.2.1.6. Anti-depressants
      • 4.2.1.7. Other Non-narcotic Analgesics
    • 4.2.2. Devices
      • 4.2.2.1. Neurostimulation Devices
      • 4.2.2.2. Brain and Spinal Cord Stimulation (SCS) Devices
      • 4.2.2.3. Analgesics Infusion Pumps
  • 4.3. By Route of Administration
    • 4.3.1. Injectable
    • 4.3.2. Oral
    • 4.3.3. Topical
    • 4.3.4. Transdermal
    • 4.3.5. Others
  • 4.4. By Distribution Channel
    • 4.4.1. Hospital Pharmacies
    • 4.4.2. Retail Pharmacies
    • 4.4.3. Online Pharmacies
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia-Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East and Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Postoperative Pain Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Product
      • 5.1.2.1. Drugs
      • 5.1.2.1.1. Opioids
      • 5.1.2.1.2. Cyclooxygenase-2-Selective(COX-2),Inhibitors
      • 5.1.2.1.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
      • 5.1.2.1.4. Anesthetics
      • 5.1.2.1.5. Anticonvulsants
      • 5.1.2.1.6. Anti-depressants
      • 5.1.2.1.7. Other Non-narcotic Analgesics
      • 5.1.2.2. Devices
      • 5.1.2.2.1. Neurostimulation Devices
      • 5.1.2.2.2. Brain and Spinal Cord Stimulation (SCS) Devices
      • 5.1.2.2.3. Analgesics Infusion Pumps
    • 5.1.3. By Route of Administration
      • 5.1.3.1. Injectable
      • 5.1.3.2. Oral
      • 5.1.3.3. Topical
      • 5.1.3.4. Transdermal
      • 5.1.3.5. Others
    • 5.1.4. By Distribution Channel
      • 5.1.4.1. Hospital Pharmacies
      • 5.1.4.2. Retail Pharmacies
      • 5.1.4.3. Online Pharmacies
    • 5.1.5. United States*
      • 5.1.5.1. Market Size & Forecast
      • 5.1.5.1.1. By Value
      • 5.1.5.1.2. By Volume
      • 5.1.5.2. By Product
      • 5.1.5.2.1. Drugs
      • 5.1.5.2.1.1. Opioids
      • 5.1.5.2.1.2. Cyclooxygenase-2-Selective(COX-2),Inhibitors
      • 5.1.5.2.1.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
      • 5.1.5.2.1.4. Anesthetics
      • 5.1.5.2.1.5. Anticonvulsants
      • 5.1.5.2.1.6. Anti-depressants
      • 5.1.5.2.1.7. Other Non-narcotic Analgesics
      • 5.1.5.2.2. Devices
      • 5.1.5.2.2.1. Neurostimulation Devices
      • 5.1.5.2.2.2. Brain and Spinal Cord Stimulation (SCS) Devices
      • 5.1.5.2.2.3. Analgesics Infusion Pumps
      • 5.1.5.3. By Route of Administration
      • 5.1.5.3.1. Injectable
      • 5.1.5.3.2. Oral
      • 5.1.5.3.3. Topical
      • 5.1.5.3.4. Transdermal
      • 5.1.5.3.5. Others
      • 5.1.5.4. By Distribution Channel
      • 5.1.5.4.1. Hospital Pharmacies
      • 5.1.5.4.2. Retail Pharmacies
      • 5.1.5.4.3. Online Pharmacies
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Product
  • 6.2. By Route of Administration
  • 6.3. By Distribution Channel
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Novartis AG
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Allergan plc
  • 13.3. Teva Pharmaceutical Industries Ltd.
  • 13.4. Mylan N.V.
  • 13.5. Pfizer Inc.
  • 13.6. GlaxoSmithKline Plc.
  • 13.7. Johnson & Johnson Pte. Ltd.
  • 13.8. AstraZeneca PLC
  • 13.9. Sanofi S.A.
  • 13.10. Cipla Inc. (InvaGen Pharmaceuticals Inc.)

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 4. Global Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 5. Global Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 6. Global Postoperative Pain Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 9. North America Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 10. North America Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 11. North America Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 12. North America Postoperative Pain Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 15. United States Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 16. United States Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 17. United States Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 18. Canada Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 20. Canada Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 21. Canada Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 22. Canada Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 23. Mexico Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Mexico Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 26. Mexico Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 27. Mexico Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 28. Europe Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Europe Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 31. Europe Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 32. Europe Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 33. Europe Postoperative Pain Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 36. Germany Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 37. Germany Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 38. Germany Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 39. France Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 41. France Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 42. France Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 43. France Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 44. Italy Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Italy Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 47. Italy Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 48. Italy Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 49. United Kingdom Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 51. United Kingdom Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 52. United Kingdom Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 53. United Kingdom Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 54. Russia Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 56. Russia Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 57. Russia Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 58. Russia Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 59. Netherlands Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 61. Netherlands Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 62. Netherlands Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 63. Netherlands Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 64. Spain Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. Spain Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 67. Spain Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 68. Spain Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 69. Turkey Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Turkey Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 72. Turkey Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 73. Turkey Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 74. Poland Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 76. Poland Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 77. Poland Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 78. Poland Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 79. South America Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 81. South America Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 82. South America Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 83. South America Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 84. South America Postoperative Pain Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 87. Brazil Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 88. Brazil Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 89. Brazil Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 90. Argentina Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Argentina Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 93. Argentina Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 94. Argentina Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 95. Asia-Pacific Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 97. Asia-Pacific Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 98. Asia-Pacific Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 99. Asia-Pacific Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100. Asia-Pacific Postoperative Pain Market Share (%), By Country, 2017-2031F
  • Figure 101. India Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 103. India Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 104. India Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 105. India Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 106. China Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. China Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 109. China Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 110. China Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 111. Japan Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 113. Japan Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 114. Japan Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 115. Japan Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 116. Australia Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 118. Australia Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 119. Australia Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 120. Australia Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 121. Vietnam Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 123. Vietnam Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 124. Vietnam Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 125. Vietnam Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 126. South Korea Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 128. South Korea Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 129. South Korea Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 130. South Korea Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 131. Indonesia Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 133. Indonesia Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 134. Indonesia Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 135. Indonesia Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 136. Philippines Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 138. Philippines Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 139. Philippines Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 140. Philippines Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 141. Middle East & Africa Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 143. Middle East & Africa Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 144. Middle East & Africa Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 145. Middle East & Africa Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 146. Middle East & Africa Postoperative Pain Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 149. Saudi Arabia Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 150. Saudi Arabia Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 151. Saudi Arabia Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 152. UAE Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 154. UAE Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 155. UAE Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 156. UAE Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 157. South Africa Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 159. South Africa Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 160. South Africa Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 161. South Africa Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 162. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023